Long-Term Use of Benralizumab Appears Safe, Effective for Severe Asthma

Embargoed Until May 20, 9:15 a.m. CT

FOR MORE INFORMATION, CONTACT:

Dacia Morris
[email protected]
ATS Office 212-315-8620 (until May 16)

Session: B21 Severe Asthma: Clinical and Mechanistic Studies 
Abstract Presentation Time: Monday, May 20, 9:15 a.m. CT
Location: Room D222-D224 (Level 2), Kay Bailey Hutchison Convention Center Dallas

LONG-TERM USE OF BENRALIZUMAB APPEARS SAFE, EFFECTIVE FOR SEVERE ASTHMA

Newswise — ATS 2019, Dallas, TX ─ Patients with severe eosinophilic asthma, who participated in three different Phase 3 trials of benralizumab (brand name Fasenra) and then enrolled in a long-term trial of the drug’s efficacy and safety, continued to experience fewer exacerbations and improved pulmonary function and quality of life, according to research presented at ATS 2019. The continuation study, named BORA, found that the risk of infection did not increase over time and that long-term treatment with benralizumab was well tolerated and did not lead to new safety concerns.

VIEW ABSTRACT

CONTACT FOR MEDIA
J. Mark FitzGerald
[email protected]